FIND OUT WHY THIS IS SO IMPORTANT FOR YOUR PET
MICROBIOTA
In memories of all immobile dogs that were not given a second chance
What is Microbiota?
A microbiota is an “ecological community of commensal, symbiotic and pathogenic microorganisms” found in and on all multicellular organisms studied to date from plants to animals. A microbiota includes bacteria, archaea, protists, fungi and viruses. Microbiota have been found to be crucial for immunologic, hormonal and metabolic homeostasis of their host. The synonymous term microbiome describes either the collective genomes of the microorganisms that reside in an environmental niche or the microorganisms themselves.
The intestinal microbiota is associated closely with health and disease. This Insight explores human developmental biology from a microbial perspective; the influence of diet and the microbiota on metabolism; the microbiota and innate immunity; the microbiota and adaptive immunity; how the microbiota and pathogenic bacteria interact in the gut; and the promise of microbiome-wide association studies for precision medicine.
Scientific research now shows that a prolific and balanced intestinal microbiota is more critical to your health than you ever imagined.
Dr Jean Paul Ly, Senior Veterinarian and Founder of ARC Health Services.
The food we eat plays an essential role in maintaining the diversity and proper functioning of our gut microbiota. When talking about gut microbiota, it could be said that “we are what we eat”, as what we consume also feeds off the hundreds of trillions of bacteria living in our digestive system. For this reason, a varied and balanced diet is essential.
The food we eat also plays an essential role in maintaining the diversity and proper functioning of our gut microbiota. Prebiotics and probiotics are two of the most widely studied elements in the field of gut microbiota. Both have effects that are considered beneficial for the gut microbiota which impacts various functions of the body such as the digestive condition, for this reason, specialists highlight the importance of including both of them in our diet, in order to promote a healthy microbiota.
VETERINARIAN REFERENCES
Alana Redfern, DVM, MSc
Department of Internal Medicine, BluePearl Veterinary Partners, New York City, New York, USA
Jan Suchodolski, DrVetMed, PhD, AGAF, DACVIM
Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, USA
Albert Jergens, DVM, MS, PhD, DACVIM
Department of Small Animal Internal Medicine, Iowa State University College of Veterinary Medicine, Ames, Iowa, USA
Gregory J Phillips M.A., Ph.D.
Pfizer award for research excellence in veterinary medicine (2005)
Jan S. Suchodolski, MedVet, DrVetMed, PhD, AGAF, DACVM
Texas A&M Veterinary Medicine & Biomedical Sciences
Erika de Papp, DVM, DACVIM
Special interests include gastrointestinal endoscopy, cystoscopy, endocrinology and hematologic disorders.
INTRODUCTION T0 MICROBIOTA
The intestinal microbiota can be defined as the dynamic collection of microorganisms within the gastrointestinal (GI) tract and the system of interactions these organisms have with each other and with the host cells. Molecular tools have allowed us to characterize the intestinal microbiota of dogs and cats in more detail. Comparative analyses of the bacterial 16S rRNA gene have provided vast amounts of phylogenetic data from both healthy and diseased animals (Suchodolski et al., 2008a; Handl et al., 2011). More recent functional approaches including metagenomics and metabolomics have begun to relate phylogenetic information to physiologic function (Swanson et al., 2011; Deusch et al., 2014). The intestinal microbiota is a dynamic system and the composition varies within an individual (i.e., different locations of the GI tract, luminal vs. mucosa-adherent, or different time points; Ritchie et al., 2008; Suchodolski et al., 2008a) as well as between individuals (Desai et al., 2009). The composition can also be influenced by diet (Lubbs et al., 2009; Swanson et al., 2011; Deusch et al., 2014), antibiotics (Suchodolski et al., 2009; Igarashi et al., 2014), GI disease (Inness et al., 2007; Guard et al., 2015), age (Deusch et al., 2015), and other genetic and environmental factors. The intestinal microbiota has several roles in the maintenance of host health including defending against non-resident intestinal pathogens, aiding in development of a healthy epithelium and immune system, and providing nutrients for the host via fermentative and metabolic activities (Suchodolski, 2011). It is these complex interactions among the microbiota, immune system, and host genetics that influence the balance between health and disease. This review will characterize the healthy intestinal microbiome, summarize methods of characterization, and discuss changes that occur in dogs and cats with gastrointestinal diseases.
BACKGROUND
The term probiotic is currently used to name ingested microorganisms associated with benefits for humans and animals. The term came into more common use after 1980. The introduction of the concept (but not the term) is generally attributed to Nobel laureate Élie Metchnikoff, who postulated that yogurt-consuming Bulgarian peasants lived longer lives because of this custom. He suggested in 1907 that “the dependence of the intestinal microbeson the food makes it possible to adopt measures to modify the flora in our bodies and to replace the harmful microbes by useful microbes. A significant expansion of the potential market for probiotics has led to higher requirements for scientific substantiation of putative benefits conferred by the microorganisms.
Recently there has been a move away from probiotics from milk cultures as it is rationalised that the normal gut flora in animals are not milk based. Better results are seen when fecal microbiota are administered. Fecal Microbiota transplant or simply poo transplant has been undergoing an explosive revival in the medical community. The concept of treating fecal diseases with fecal matter originated in China millennia ago. Fourth century Chinese medical literature mentions it to treat food poisoning and severe diarrhea. In veterinary medicine it has been used by farm veterinarians for centuries in treating scours and digestive disorders. Fecal microbiota transplant has been known as “transfaunation” and is used to treat ruminating animals, like cows and sheep, by feeding rumen contents of a healthy animal to another individual of the same species in order to colonize its gastrointestinal tract with normal bacteria.[51]
Medical research into microbiome therapies has revealed surprisingly results in the treatment of recurrent chronic gastrointestinal disease such as inflammatory bowel disease and many digestive disorders. Other improved conditions attributed to fecal microbiota transplants include new hair growth in alopecia universalis, depression relief, acne resolution, improved liver values and general immune recovery.
Microbiota transplants has superceeded the previously used milk based probiotics by proving itself to be more effective and normal
WHAT IS IT USED FOR
It is well known that the innate immune system (white blood cells ) provide the first line of defence to the body and play a major role in recovery. Research has shown that Biological Response Modifier (BRM) or immune modulators act directly on the Innate immune elements like the white blood cells. Superbiolite are very rich in BRM and is a safe, effective immunomodulator acting mainly on the white blood cells. The frequent intake of Superbiolite probiotics reduces the risk of ‘Leaky Gut’ syndrome that plaques thousands of animals on probiotic deficient diets especially highly processed foods The Superbiolite Microbiota with the zeolite, aids in the reduction of toxic gastrointestinal ammonia. This in turn will reduce the ammonia load on the liver, and consequential Urea load on the kidneys. For this reason, Superbiolite is useful in aiding the recovery of liver and kidney diseaes.
Superbiolite can safely be used in most species for
- IBD
- Diarrhoea
- Skin problems
- Pancreatitis
- Immune deficiency
- Allergies
- Compromised liver function
- Kidney disease
- Neoplastic proces
- Antibiotic induced gastroenteritis
- Bloat
REFERENCES
- Rowan, Karen (October 20, 2012). “‘Poop Transplants’ May Combat Bacterial Infections”. LiveScience.com. Retrieved October 20, 2012.
- Bakken, Johan S.; Borody, Thomas; Brandt, Lawrence J.; Brill, Joel V.; Demarco, Daniel C.; Franzos, Marc Alaric; Kelly, Colleen; Khoruts, Alexander; Louie, Thomas; Martinelli, Lawrence P.; Moore, Thomas A.; Russell, George; Surawicz, Christina (December 1, 2011). “Treating Clostridium difficile Infection With Fecal Microbiota Transplantation”. Clinical Gastroenterology and Hepatology. 9 (12): 1044–1049. PMC 3223289 . PMID 21871249. doi:1016/j.cgh.2011.08.014.
- Burke KE, Lamont JT (August 2013). “Fecal Transplantation for Recurrent Clostridium difficile Infection in Older Adults: A Review.”. Journal of the American Geriatrics Society. 61 (8): 1394–8. PMID 23869970. doi:1111/jgs.12378.
- Drekonja, D; Reich, J; Gezahegn, S; Greer, N; Shaukat, A; MacDonald, R; Rutks, I; Wilt, TJ (May 5, 2015). “Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review.”. Annals of Internal Medicine. 162 (9): 630–8. PMID 25938992. doi:7326/m14-2693.
- Kelly CR; De Leon L; Jasutkar N (2012). “Fecal Microbiota Transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results”. J Clin Gastroenterol. 46 (2): 145–149. PMID 22157239. doi:1097/MCG.0b013e318234570b.
- Brandt LJ; Borody TJ; Campbell J. (Sep 2011). “Endoscopic Fecal Microbiota Transplantation: first-line treatment for severe Clostridium difficile infection?”. J Clin Gastroenterol. 45 (8): 655–657. PMID 21716124. doi:1097/MCG.0b013e3182257d4f.
- Bakken JS (Dec 2009). “Fecal bacteriotherapy for recurrent Clostridium difficile infection”. Anaerobe. 15 (6): 285–289. PMID 19778623. doi:1016/j.anaerobe.2009.09.007.
- Floch MH (2010). “Fecal Bacteriotherapy, Fecal Transplant and the Microbiome”. J Clin Gastroenterol. 44 (8): 529–530. PMID 20601895. doi:1097/MCG.0b013e3181e1d6e2.
- Borody TJ, Campbell J (2011). “Fecal microbiota transplantation: current status and future directions”. Exp Rev Gastroenterol Hepatol. 5 (6): 653–655. PMID 22017691. doi:1586/egh.11.71.
- Baxter, M; Colville, A (February 2016). “Adverse events in faecal microbiota transplant: a review of the literature.”. The Journal of hospital infection. 92 (2): 117–27. PMID26803556. doi:1016/j.jhin.2015.10.024.
- Preeti Malani (October 4, 2013). “Fecal transplant pill effective against recurrent Clostridium difficile infection”. news@JAMA.
- Borody TJ, Khoruts A (December 20, 2011). “Fecal microbiota transplantation and emerging applications”. Nature Reviews Gastroenterology & Hepatology. 9 (2): 88–96. PMID22183182. doi:1038/nrgastro.2011.244.
- Smits LP; Bouter KE; de Vos WM; Borody TJ; Nieuwdorp M (November 2013). “Therapeutic potential of fecal microbiota transplantation”. Gastroenterology. 145 (5): 946–53. PMID24018052. doi:1053/j.gastro.2013.08.058.
- Borody TJ, Leis S, Pang G et al. Fecal Bacteriotherapy in the treatment of recurrent Clostridium difficile UpToDate
- Eiseman B, Silen W, Bascom GS, et al. (1958). “Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis”. Surgery. 44 (5): 854–859. PMID13592638.
- Lund-Tonnesen S, Berstad A, Schreiner A, et al. (1998). “Clostridium-difficile-associated diarrhea treated with homologous feces”. Tidsskr nor Laegeforen. 118 (7): 1027–1030. PMID9531822.
- Persky SE, Brandt LJ (2000). “Treatment of recurrent Clostridium-difficile-associated diarrhea by administration of donated stool directly through a colonoscope”. Am J Gastroenterol. 95 (11): 3283–3285. PMID11095355. doi:1111/j.1572-0241.2000.03302.x.
- Cammarota, G.; Masucci, L.; Ianiro, G.; Bibbò, S.; Dinoi, G.; Costamagna, G.; Sanguinetti, M.; Gasbarrini, A. (2015). “Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection”. Aliment Pharmacol Ther. 41 (9): 835–843. PMID25728808. doi:1111/apt.13144.
- van Nood E; Vrieze A; Nieuwdorp M; et al. (Jan 2013). “Duodenal infusion of donor feces for recurrent Clostridium difficile”. N Engl J Med. 368 (5): 407–15. PMID23323867. doi:1056/NEJMoa1205037.
- Martin WJ (2009). “Encapsulated Medicines for Iatrogenic Diseases”. British Patent Application: GB0916335.3.
- Hamilton MJ; Weingarden AR; Sadowsky MJ; Khoruts A (2012). “Standardised frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection”. Am J Gastroenterol. 107 (5): 761–767. PMID22290405. doi:1038/ajg.2011.482.
- Hamilton MJ; Weingarden AR; Unno T; Khoruts A; Sadowsky MJ (2013). “High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria”. Gut Microbes. 4 (2): 1–11. doi:4161/gmic.23571.
- Smith, Peter Andrey (February 17, 2014). “A New Kind of Transplant Bank”. The New York Times. Retrieved July 10, 2014.
- Chang JY, Antopoulos DA, Kalra A, et al. (2008). “Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea”. J Infect Dis. 197 (3): 438. PMID18199029. doi:1086/525047.
- Khoruts A, Dicksved J, Jansson JK, et al. (2010). “Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea”. J Clin Gastroenterol. 44 (5): 354–360. PMID20048681. doi:1097/MCG.0b013e3181c87e02.
- Tvede M, Rask-Madsen J (1989). “Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients”. Lancet. 333 (8648): 1156–1160. doi:1016/S0140-6736(89)92749-9.
- Grehan MJ, Borody TJ, Leis SM, et al. (2010). “Durable alteration of the colonic microbiota by the administration of donor fecal flora”. J Clin Gastroenterol. 44 (8): 551–561. PMID20716985. doi:1097/MCG.0b013e3181e5d06b.
- Rea MC; Dobson A; O’Sullivan O; Crispie F; Fouhy F; Cotter PD; Shanahan F; Kiely B; Hill C; Ross RP (March 15, 2011). “Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon”. Proc Natl Acad Sci U S A. 108 (Suppl 1): 4639–4644. PMC3063588 . PMID 20616009. doi:1073/pnas.1001224107.
- Henning Gerke (December 2014). “Whats the lowdown on ‘fecal transplantation’?”. Health at Iowa. U of Iowa. Retrieved January 14, 2015.
- The Johns Hopkins Children’s Center. The Johns Hopkins University. July 29, 2013.
- Lewin, Ralph A. (2001). “More on merde”. Perspectives in Biology and Medicine. 44 (4): 594–607. PMID11600805. doi:1353/pbm.2001.0067.
- Aas, Johannes (March 1, 2003). “Recurrent Clostridium difficile Colitis: Case Series Involving 18 Patients Treated with Donor Stool Administered via a Nasogastric Tube”. Clinical Infectious Diseases. 36: 580–5.
- Seekatz, Anna (May–June 2014). “Recovery of the Gut Microbiome following Fecal Microbiota Transplantation”. mBio. 5 (3): 1–9.
- Borody TJ, Campbell J (2011). “Fecal microbiota transplantation: current status and future directions”. Expert Rev Gastroenterol Hepatol. 5 (6): 653–655. PMID22017691. doi:1586/egh.11.71.
- Bennet JD; Brinkman M (1989). “Treatment of ulcerative colitis by implantation of normal colonic flora”. Lancet. 1 (8630): 164. doi:1016/s0140-6736(89)91183-5.
- Borody T; Warren E; Leis S; Surace R; Ashman O (2003). “Treatment of ulcerative colitis using fecal bacteriotherapy”. J Clin Gastroenterol. 37 (1): 42–47. PMID12811208. doi:1097/00004836-200307000-00012.
- Borody TJ; Warren EF; Leis SM; Surace R; Ashman O; Siarakis S (2004). “Bacteriotherapy using fecal flora: toying with human motions”. J Clin Gastroenterol. 38 (6): 475–83. PMID15220681. doi:1097/01.mcg.0000128988.13808.dc.
- Borody TJ, Torres M, Campbell J, et al. (2011). “Reversal of inflammatory bowel disease (IBD) with recurrent fecal microbiota transplants (FMT)”. Am J Gastroenterol. 106: S352.
- Borody TJ; Paramsothy S; Agrawal G (2013). “Fecal Microbiota Transplantation: Indications, Methods, Evidence and Future Directions”. Curr Gastroenterol Rep. 15 (8): 337. doi:1007/s11894-013-0337-1.
- FDA struggles to regulate fecal transplants”. CBS News. Associated Press. June 26, 2014.
- van Nood E; Vrieze A; Nieuwdorp M; Fuentes S; Zoetendal EG; de Vos WM; Visser CE; Kuijper EJ; Bartelsman JF; Tijssen JG; Speelman P; Dijkgraaf MG; Keller JJ (January 16, 2013). “Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile“. N Engl J Med. 368 (5): 407–15. PMID23323867. doi:1056/NEJMoa1205037.
- Public Workshop: Fecal Microbiota for Transplantation”. Food and Drug Administration. March 10, 2014.
- 78 FR 12763, February 25, 2013
- Smith, Mark B.; Kelly, Colleen; Alm, Eric J. (February 19, 2014). “Policy: How to regulate faecal transplants”. Nature.
- AGA Confirms IND is Required for Fecal Microbiota Transplantation, American Gastroenterological Association, May 6, 2013, archived from
- Jump up ^ “Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies”. Food and Drug Administration. July 2013.
- Food and Drug Administration. March 2014.
- Gabrielle Emanuel (March 7, 2014). “MIT Lab Hosts Nation’s First Stool Bank, But Will It Survive?”. WBUR-FM.
- Ratner, Mark (May 8, 2014). “Fecal transplantation poses dilemma for FDA”. Nature Biotechnology. 32 (5): 401–402. doi:1038/nbt0514-401.
- . Bbc.co.uk. n.d. Retrieved November 27, 2011.
- DePeters EJ; George LW (September 26, 2014). “Rumen transfaunation”. Immunology Letters. 162 (2 Part A): 69–76. PMID25262872. doi:1016/j.imlet.2014.05.009.
- Dupont, HL (October 2013). “Diagnosis and management of Clostridium difficile infection.”. Clinical Gastroenterology and Hepatology. 11 (10): 1216–23; quiz e73. PMID23542332. doi:1016/j.cgh.2013.03.016.